Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSabre Insurance Group Regulatory News (SBRE)

Share Price Information for Sabre Insurance Group (SBRE)

Share Price is delayed by 15 minutes
Get Live Data
157.60    3.80 (2.47%)
Bid:
157.60
Ask:
158.00
Spread: 0.40 (0.254%)
Market Cap: £385.03m
SBRE Live PriceLast checked at - London Stock Exchange

Intraday Sabre Insurance Group Share Chart

Trading Update

11 Oct 2018 07:00

RNS Number : 6525D
Sabre Insurance Group PLC
11 October 2018
 

11 October 2018

 

SABRE INSURANCE GROUP PLC

Trading Update

Sabre Insurance Group plc (the "Group", or "Sabre"), one of the UK's leading private motor insurance underwriters, today provides a trading update for the nine months ending 30 September 2018.

Summary

· The Group continues its strategy of focusing on underwriting profitability over growth

· Superior underwriting performance, underpinned by strong claims experience in the period under review, supports the Group's continued expectation of delivering a FY 2018 combined ratio better than our mid-70%'s target and slightly higher than the FY 2017 combined ratio, which was 68.5%

· Strong organic capital generation supports the potential for an attractive full-year dividend with a solvency coverage ratio of 195%(1) as at the end of September, above our 140% - 160% target range

· Appropriate pricing actions taken to cover anticipated claims inflation, with GWP for the first nine months of the year remaining broadly flat year on year at £162.6m(1) (2017: £165.0m). The Group maintains its expectations for FY 2018 GWP to be in line with 2017

 

Geoff Carter, Chief Executive Officer, commented:

Throughout a period of strong competition in the UK motor insurance sector, we have continued to apply our core philosophy of focusing on underwriting profitability, with volume remaining an output rather than target.

As communicated earlier in the year, we have sought to cover anticipated claims inflation and will continue this focus throughout the rest of this year. Whilst premiums for Q3 2018 were slightly below a strong comparative period in Q3 2017, we remain confident that we will end the year with premium in-line with 2017.

Our absolute focus on profitability has yielded a strong underwriting result for the year to date and has allowed us to generate significant excess capital during the period under review. Having paid an interim dividend of 7.2 pence per share, the solvency capital ratio as at 30 September 2018 is at 195%, well above our target operating range of 140%-160%. This provides the Board the option to return surplus capital to shareholders following the full-year results, should the capital position improve further throughout the remainder of 2018. 

(1) Numerical information not subject to audit

 

 

Media enquiries

Tulchan Communications LLP

James Macey White, Roger Tejwani & David Ison

020 7353 4200

sabre@tulchangroup.com

 

Investor enquiries

Sabre Insurance Group plc

Adam Westwood

adam.westwood@sabre.co.uk

07776 649 119

 

LEI code: 2138006RXRQ8P8VKGV98

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTFFUFISFASELS
Date   Source Headline
2nd Jun 20267:00 amRNSOn-market Share Buyback Programme of £5m
27th May 20269:36 amRNSDirector Declaration
21st May 202611:20 amRNSResult of AGM
21st May 20267:00 amRNSTrading Update
12th May 20261:22 pmRNSDirector/PDMR Shareholding
22nd Apr 20261:18 pmRNSDirector/PDMR Shareholding
14th Apr 20263:48 pmRNSDirector/PDMR Shareholding
13th Apr 20263:18 pmRNSDirector/PDMR Shareholding
8th Apr 20262:56 pmRNSDirector/PDMR Shareholding
8th Apr 202610:41 amRNSDirector/PDMR Shareholding
8th Apr 202610:39 amRNSDirector/PDMR Shareholding
30th Mar 202611:01 amRNSNotice of AGM
11th Mar 20261:49 pmRNSDirector/PDMR Shareholding
10th Mar 20267:00 amRNSFull-year results 2025
11th Feb 20261:27 pmRNSDirector/PDMR Shareholding
13th Jan 20263:43 pmRNSDirector/PDMR Shareholding
11th Dec 20251:29 pmRNSDirector/PDMR Shareholding
11th Nov 20251:40 pmRNSDirector/PDMR Shareholding
31st Oct 20258:00 amRNSTotal Voting Rights
23rd Oct 20259:58 amRNSDirector/PDMR Shareholding
16th Oct 20257:00 amRNSTrading Update
14th Oct 20257:49 amRNSHolding(s) in Company
13th Oct 20253:56 pmRNSDirector/PDMR Shareholding
3rd Oct 20257:00 amRNSCompletion of Buyback Programme
3rd Oct 20257:00 amRNSTransaction in Own Shares
2nd Oct 20257:00 amRNSTransaction in Own Shares
1st Oct 20257:00 amRNSTransaction in Own Shares
30th Sep 202510:21 amRNSTotal Voting Rights
30th Sep 20257:00 amRNSTransaction in Own Shares
29th Sep 20257:00 amRNSTransaction in Own Shares
26th Sep 20257:00 amRNSTransaction in Own Shares
25th Sep 20251:01 pmRNSDirector/PDMR Shareholding
25th Sep 20257:00 amRNSTransaction in Own Shares
24th Sep 20257:00 amRNSTransaction in Own Shares
23rd Sep 20257:00 amRNSTransaction in Own Shares
22nd Sep 20257:00 amRNSTransaction in Own Shares
19th Sep 20257:00 amRNSTransaction in Own Shares
18th Sep 20254:52 pmRNSHolding(s) in Company
18th Sep 20257:00 amRNSTransaction in Own Shares
17th Sep 20257:00 amRNSTransaction in Own Shares
16th Sep 20257:00 amRNSTransaction in Own Shares
15th Sep 20257:00 amRNSTransaction in Own Shares
12th Sep 20257:00 amRNSTransaction in Own Shares
11th Sep 202512:24 pmRNSDirector/PDMR Shareholding
11th Sep 20257:00 amRNSTransaction in Own Shares
10th Sep 20257:00 amRNSTransaction in Own Shares
9th Sep 20257:00 amRNSTransaction in Own Shares
8th Sep 20257:00 amRNSTransaction in Own Shares
5th Sep 20257:00 amRNSTransaction in Own Shares
4th Sep 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.